ScienceRising US scrutiny of clinical trials could threaten China’s biotech edge: analysts

Analysts say China’s fast, cost-effective early clinical trials have helped it become a global biopharmaceutical powerhouse. US lawmakers and FDA officials have warned about American drugmakers’ growing reliance on trials in China, citing concerns over the process’s opacity and the need to protect medical interests.

China biotechclinical trialsUS regulation

SSouth China Morning Post★★★☆☆2026-09-23 02:00Original